OBIGEN PHARMA

Established in 2020, OBIGEN Pharma, a subsidiary of OBI Pharma, is the first biotech startup in Taiwan specializing in the research, development, production, and manufacturing of Botulinum toxin. Their type A botulinum toxin, OBI-858, originates from an API plant adhering to the PIC/s GMP standards in the Zhubei Biomedical Science Park and a high-security sterile drug product plant in the Tainan Science Park. Guided by diligent efforts, OBIGEN develops and produces stable quality products, contributing to advancing the entire medical industry. With a dedicated focus on innovation and vitality, OBIGEN actively forges international partnerships to globally launch the exceptional Taiwan toxin.